TheraPanacea, an award-winning medical technology company created in 2017, is reinventing healthcare through harnessing AI to develop cutting-edge software to optimize diagnostics, prognostics and therapies for cancer and other complex diseases. We offer pioneering holistic approaches for cancer research and treatment based on a multi-scale integration of medicine, information theory, data curation and computational medicine.
At TheraPanacea we are devoted to unlock the unlimited power of AI-based software to drive innovation in healthcare. Endowed with an excellent IP portfolio, our vision is to exploit state-of-the-art research technology to accelerate health care’s transition towards predictive, evidence-driven, adaptive treatment planning and delivery.
Our mission is to improve patient’s quality of life by enabling health care providers to design smarter treatment plans, work more effectively, and reduce toxic side effects. To bring these much needed advancements faster to the patient, we count on a multitude of collaborations with leading cancer centers and industrial partners all around the world.
Through our first product, ART-Plan™, we leverage state-of-the-art advancements in artificial intelligence, data science and medical image processing to benefit patients and medical teams alike. An intelligent software suite delivering high-precision radiotherapy, ART-Plan™ enables optimization of every step of the treatment process flow: from preparation to follow-up. In the past six months, more than 20 leading radiotherapy centers in Europe have adopted ART-Plan™ in their clinical routine. Are you ready to reinvent cancer care through AI?
Up to
90%of time saved in contouring
Full-body delineation achieved in
2minutesMore than
80OARs and CTVs delineated automatically
More than
20centres using ART-Plan™ in Europe
More than
15000patients treated with ART-Plan™
Clinical trials for pharmaceutical and medical purposes are time consuming, expensive, and often burdensome on patients. Flawed study designs, lack of quantitative measures for early assessment, or inappropriate sample sizes are all challenges that lead to the failure of most clinical trials.
To overcome these challenges, accelerate drug discovery and reduce patient burden, TheraPanacea is developing the first AI-powered radiomics platform for precision medicine and drug development: ART-Omics™.
ART-Omics™ integrates unsupervised biomarker discovery with clinical domain knowledge to offer a unique combination to auto-identify correlation of hidden variables that are invisible to the human eye and predict patient-specific clinical trial outcome. What is more, thanks a holistic biomarker discovery, ART-Omics™ will include advanced prognosis tools that can be used for inclusion criteria in the study as well as continuous assessment of patients response throughout the treatment.
Soon, ART-Omics™ will become a strategic ally to pharmaceutical companies to provide tailor-made Ai-based, radiomic algorithms to accelerate therapeutic development and consequently reduce costs related to long or unsuccessful trials.
ART-Omics™ offers a plug-and-play radiomics platform for pharmaceutical companies.
Since its creation, TheraPanacea has won prestigious distinctions and prizes including:
